| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Institut Pasteur de Lille, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 545, and Université de Lille 2, Faculté des Sciences Pharmaceutiques et Biologiques et Faculté de Médecine, Lille; INSERM, U 915, Université de Nantes, Faculté de Médecine, and Clinique d'Endocrinologie, Institut du Thorax, Nantes, France; and Center for Liver, Digestive, and Metabolic Diseases, Laboratory of Pediatrics, University Medical Center Groningen, Groningen, The Netherlands
The incidence of the metabolic syndrome has taken epidemic proportions in the past decades, contributing to an increased risk of cardiovascular disease and diabetes. The metabolic syndrome can be defined as a cluster of cardiovascular disease risk factors including visceral obesity, insulin resistance, dyslipidemia, increased blood pressure, and hypercoagulability. The farnesoid X receptor (FXR) belongs to the superfamily of ligand-activated nuclear receptor transcription factors. FXR is activated by bile acids, and FXR-deficient (FXR–/–) mice display elevated serum levels of triglycerides and high-density lipoprotein cholesterol, demonstrating a critical role of FXR in lipid metabolism. In an opposite manner, activation of FXR by bile acids (BAs) or nonsteroidal synthetic FXR agonists lowers plasma triglycerides by a mechanism that may involve the repression of hepatic SREBP-1c expression and/or the modulation of glucose-induced lipogenic genes. A cross-talk between BA and glucose metabolism was recently identified, implicating both FXR-dependent and FXR-independent pathways. The first indication for a potential role of FXR in diabetes came from the observation that hepatic FXR expression is reduced in animal models of diabetes. While FXR–/– mice display both impaired glucose tolerance and decreased insulin sensitivity, activation of FXR improves hyperglycemia and dyslipidemia in vivo in diabetic mice. Finally, a recent report also indicates that BA may regulate energy expenditure in a FXR-independent manner in mice, via activation of the G protein-coupled receptor TGR5. Taken together, these findings suggest that modulation of FXR activity and BA metabolism may open new attractive pharmacological approaches for the treatment of the metabolic syndrome and type 2 diabetes.
This article has been cited by other articles:
|
|
 |
|
  R. Cao, Z. X. Cronk, W. Zha, L. Sun, X. Wang, Y. Fang, E. Studer, H. Zhou, W. M. Pandak, P. Dent, et al. Bile acids regulate hepatic gluconeogenic genes and farnesoid X receptor via G{alpha}i-protein-coupled receptors and the AKT pathway J. Lipid Res., August 1, 2010; 51(8): 2234 - 2244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hageman, H. Herrema, A. K. Groen, and F. Kuipers A Role of the Bile Salt Receptor FXR in Atherosclerosis Arterioscler Thromb Vasc Biol, August 1, 2010; 30(8): 1519 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Y. Lee, T. Q. de Aguiar Vallim, H. K. Chong, Y. Zhang, Y. Liu, S. A. Jones, T. F. Osborne, and P. A. Edwards Activation of the Farnesoid X Receptor Provides Protection against Acetaminophen-Induced Hepatic Toxicity Mol. Endocrinol., August 1, 2010; 24(8): 1626 - 1636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Chen, J. McNulty, D. Anderson, Y. Liu, C. Nystrom, S. Bullard, J. Collins, A. L. Handlon, R. Klein, A. Grimes, et al. Cholestyramine Reverses Hyperglycemia and Enhances Glucose-Stimulated Glucagon-Like Peptide 1 Release in Zucker Diabetic Fatty Rats J. Pharmacol. Exp. Ther., July 1, 2010; 334(1): 164 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Martin and J. J. Tremblay Nuclear Receptors in Leydig Cell Gene Expression and Function Biol Reprod, July 1, 2010; 83(1): 3 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. Bartley, W. Yokoyama, S. A. Young, W. H. K. Anderson, S.-C. Hung, D. R. Albers, M. L. Langhorst, and H. Kim Hypocholesterolemic Effects of Hydroxypropyl Methylcellulose Are Mediated by Altered Gene Expression in Hepatic Bile and Cholesterol Pathways of Male Hamsters J. Nutr., July 1, 2010; 140(7): 1255 - 1260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Miyazaki-Anzai, M. Levi, A. Kratzer, T. C. Ting, L. B. Lewis, and M. Miyazaki Farnesoid X Receptor Activation Prevents the Development of Vascular Calcification in ApoE-/- Mice With Chronic Kidney Disease Circ. Res., June 25, 2010; 106(12): 1807 - 1817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Han, T. Li, E. Ellis, S. Strom, and J. Y. L. Chiang A Novel Bile Acid-Activated Vitamin D Receptor Signaling in Human Hepatocytes Mol. Endocrinol., June 1, 2010; 24(6): 1151 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. P. Rhee, A. Souza, L. Farrell, M. R. Pollak, G. D. Lewis, D. J. R. Steele, R. Thadhani, C. B. Clish, A. Greka, and R. E. Gerszten Metabolite Profiling Identifies Markers of Uremia J. Am. Soc. Nephrol., June 1, 2010; 21(6): 1041 - 2051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Chong, A. M. Infante, Y. K. Seo, T. I. Jeon, Y. Zhang, P. A. Edwards, X. Xie, and T. F. Osborne Genome-wide interrogation of hepatic FXR reveals an asymmetric IR-1 motif and synergy with LRH-1 Nucleic Acids Res., May 18, 2010; (2010) gkq397v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Li, D. Chanda, Y. Zhang, H.-S. Choi, and J. Y. L. Chiang Glucose stimulates cholesterol 7{alpha}-hydroxylase gene transcription in human hepatocytes J. Lipid Res., April 1, 2010; 51(4): 832 - 842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. F. Hofmann, L. R. Hagey, and M. D. Krasowski Bile salts of vertebrates: structural variation and possible evolutionary significance J. Lipid Res., February 1, 2010; 51(2): 226 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Dawson, T. Lan, and A. Rao Bile acid transporters J. Lipid Res., December 1, 2009; 50(12): 2340 - 2357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Duez and B. Staels Rev-erb-{alpha}: an integrator of circadian rhythms and metabolism J Appl Physiol, December 1, 2009; 107(6): 1972 - 1980. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Fickert, A. Fuchsbichler, T. Moustafa, M. Wagner, G. Zollner, E. Halilbasic, U. Stoger, M. Arrese, M. Pizarro, N. Solis, et al. Farnesoid X Receptor Critically Determines the Fibrotic Response in Mice but Is Expressed to a Low Extent in Human Hepatic Stellate Cells and Periductal Myofibroblasts Am. J. Pathol., December 1, 2009; 175(6): 2392 - 2405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Staels and V. A. Fonseca Bile Acids and Metabolic Regulation: Mechanisms and clinical responses to bile acid sequestration Diabetes Care, November 1, 2009; 32(suppl_2): S237 - S245. [Full Text] [PDF]
|
|
|
|
|
|
J. Y. L. Chiang Bile acids: regulation of synthesis J. Lipid Res., October 1, 2009; 50(10): 1955 - 1966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. L. Csanaky, L. M. Aleksunes, Y. Tanaka, and C. D. Klaassen Role of hepatic transporters in prevention of bile acid toxicity after partial hepatectomy in mice Am J Physiol Gastrointest Liver Physiol, September 1, 2009; 297(3): G419 - G433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Hylemon, H. Zhou, W. M. Pandak, S. Ren, G. Gil, and P. Dent Bile acids as regulatory molecules J. Lipid Res., August 1, 2009; 50(8): 1509 - 1520. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
